New non-nuke approved

A new Non-Nucleoside Reverse Transcriptase Inhibitor [1]A type of anti-HIV drug which works by interfering with an enzyme, reverse transcriptase, that HIV needs to reproduce. – etravirine – will be listed on the Pharmaceutical Benefits Scheme [2][Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs. (PBS) from July 1.

Non-nukes form an important backbone of many people’s drug regimens however resistance to the two others currently prescribed – nevirapine and efavirenz – is common. Fortunately, etravirine has proved effective in many people who are resistant [3]HIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. to these drugs.

Its addition to the antiretrovirals [4]A medication or other substance which is active against retroviruses such as HIV. currently available in Australia will benefit many of the more treatment-experienced. Its indication for use targets those who have had at least three treatment combinations fail in their therapy history.